1 Implementing Genomics and Precision Medicine in Canada Dr. Catalina Lopez-Correa CSO & VP Sector Development at Genome British Columbia 6 th Munich Biomarker Conference November 30 th , 2016 Why Genomics? “What physics was to the 20 th century, biology will be to the 21 st ” The Economist, Jun. 2007
18
Embed
Why Genomics? - BioM · Genomics Big Data (Data integration, data sharing) Infrastructure (Biobanking, Sequencing, etc) Delivery/Access (policy, reimbursement, economics, etc) Implementation
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
Implementing Genomics and Precision Medicine in Canada
Dr. Catalina Lopez-Correa
CSO & VP Sector Development at Genome British Columbia
6th Munich Biomarker Conference
November 30th, 2016
Why Genomics?
“What physics was to the 20th century, biology will be to the 21st” The Economist, Jun. 2007
2
Canada’s Genomics Enterprise
• 6 regional Genome Centres
• 10 Genomic Innovation
Network Nodes
• 210+ large-scale research
projects/initiatives funded
across all life science sectors
• 45 HQP on average,
per project
• 58+ companies created
or enhanced
3
Genome BC - History
• Co-founded by the late Dr. Michael Smith, Nobel Laureate, Genome British Columbia was formed in July 2000
• Vision: Genome Sciences will revolutionize many aspects of our lives and provide solutions to humankind’s challenges.
• Invest $340M into Discovery, Applied and Translational research key
to Life Sciences jobs plan
• With $85M from the Province, attract $255M from partner co-investors for genomics R&D
• Focus on sector-driven research to deliver economic and social benefit of BC
• Continue to enhance BC’s national/international competitiveness for scientific excellence in genomics
• Drive opportunities for BC through 2020 and beyond
11
Genome BC’s 2015-2020 Plan – Key Themes
Maintaining a world-class genomics region
• Enhance BC’s capacity for world-class genomics research • Balance a portfolio of discovery and user driven applied and translational research • Support BC’s research universities, research institutes and teaching hospitals • Attract and support the best talent
Building BC’s bioeconomy and engaging with sectors
• Attract federal and other co-investment, including private and foreign funds • Increase interaction with industry, users, and investors in key sectors • Engage with industry through Public/Private Partnerships, such as
sector innovation centres • Target investment through sector specific programs
Education
• Continue to enhance the education of the next generation of genomics scientists
12
7
Companies Advanced by Genome BC (38) 38 Companies Advanced by Genome BC:
Safer prenatal screening solution (each year 10,000 amniocentesis cause the loss of 70 healthy fetuses). NIPT is revolutionizing prenatal care.
New genomic technologies allow the detection fetal genetic abnormalities in maternal blood. Equip decision makers, pregnant women and their partner to make informed choices pertaining to prenatal genetic screening and diagnosis. High demand from the public for test coverage of NIPT – health care decision-makers will use project results to decide on coverage policies.
10
From years to days: RapidOmics Researchers: Jan Christilaw, Jan Friedman, Alison Elliot and Horacio Osiovich
Genetic disorders are a leading cause of infant mortality and make up a large percentage of the patients in BC NICU’s
An accurate and rapid diagnosis can guide treatment decisions but this is currently a significant challenge RapidOmics: pilot study exome sequencing 25 trios (baby + parents) provide results in 5-7 days This proof-of-concept could replace hundreds of different tests, improving outcomes and saving the system money
BC pharmacists leading precision medicine Researcher: Corey Nislow
Approximately 50% of all emergency department visits each year are due to adverse reactions to medications in adults aged 50 and over
Across BC, 33 community pharmacies have taken part in North America’s first project to implement pharmacogenomics
Extract DNA from Saliva, sequence DNA and prescribe
the right drug to the right patient at the right time
and right dose
11
Combatting “lung attacks”
• Blood test that will identify patients at high risk for Chronic Obstructive Pulmonary Disease (COPD).
• Marker panel is in development; refining selected markers.
• Test will improve treatment, lead to patients with fewer attacks and reduced hospitalization and emergency visits.
The project is led by Dr. Don Sin, St. Paul’s Hospital, University of British Columbia
Leading the world in HIV/AIDS research Researchers: Julio Montaner and Richard Harrigan
In Canada over 70,000 people are infected with HIV and nearly $1 billion is spent on HIV drug cocktail therapies each year
The BC Centre for Excellence is HIV/AIDS is leading the world to reduce HIV/AIDS global burden
by 90 % in 2030
Genome BC is supporting the BCCfE in developing an HIV drug-resistance test, real-time drug resistance surveillance and better methods for personalizing treatment of HIV based on each patient’s unique DNA
12
The Personalized Onco-Genomics (POG) Program Researchers: Janessa Laskin and Marco Marra
This BC Cancer Agency project looks at the specific mutations that cause cancer.
350 patients have received personalized treatment, based on their DNA
representing 50 different cancer types.
The next phase: More patients, more cancers
Doctors can then customize treatment
options to target those mutations,
increase efficacy and reduce overall cost
Path to the clinic
Centre for
Clinical Genomics
“Test” e.g.
Hereditary cancer panel
Oncopanel
Myeloid Panel
Ethics
Privacy
Economic evaluation
Populations
(BC and beyond)
13
Genome BC’s strategy for investment in health
25
Invest in genomic health research across diseases based on merit and potential impact
Enable targeted application of genomics at the level of populations Genome BC
focus areas MIND THE GAP
External guidance Research Oversight Committee
Common requirements
Cancer Infectious diseases
Rare diseases Pharmaco-genomics
Oversight Committee
Funding / partners
Genome BC, Genome Canada, CIHR, Industry partners, other partners
Stakeholder Research
Establish Health Sector Task Force
Consultations
Draft Health Sector Strategy
Health Sector Strategy
Genome BC Health Strategy
Rare diseases
Pharmacogenomics
Infectious disease
Cancer
Exemplars
Genome BC Health strategy
26
14
Total GBC investment in four priority areas
27
Infections Diseases
Cancer
HIV (UPP), Bridges (PP)
POG (SI), BIX (PP)
Rare Diseases
CAUSES (SI), iTarget (SI)
Pharmaco- Genomics
DynaCare (GAPP), BCPharma (UPP)
$2,6 M
$0.4 M
$1,7 M
$0,6M
Total GBC investment ~ $5,4M
Implementation Barriers
1. Lack of coordination and centralization
2. Need to stablish an official mechanism of Genomic Data Sharing (GDS)
3. Bioinformatics focusing mostly on research instead of data interpretation and data integration into the clinic
4. Limited number of Genetic Counselors & Bioinformatics (interpretation)
5. Several EHR systems are being used (work in isolation and implementation varies greatly between regions)
6. Lack of unique/harmonized system to evaluate new technologies (NICE, FDA)